Neoplasms Clinical Trial
Official title:
A Pilot Study Evaluating the Assessment Process for Constipation in Pediatric Oncology Patients Who Are Receiving Vinca Alkaloids and/or Narcotics
This study will evaluate a questionnaire for measuring constipation in children with cancer.
The questionnaire used in this study (Constipation Assessment Scale) reliably predicts the
presence and severity of constipation in adult patients, but has not been tested in
children. The answers to the questionnaire will be used to determine the child's level of
constipation and to plan and provide appropriate care.
Patients up to 21 years of age who are enrolled in National Cancer Institute trials and are
taking weekly vinca alkaloids or narcotics twice a day or more may be eligible for this
study.
On admission to the study, participants will undergo the following procedures:
- The child (or the child's parent) will be interviewed about the child's bowel habits.
- The results of the child's most recent physical examination related to bowel function
will be obtained from the medical record for review.
- A registered dietitian will interview the child or parent about the child's eating
habits.
During the study, participants will undergo the following procedures:
- A registered nurse will interview the child or parent about the child's bowel
movements. This will be done every other day for hospitalized children and three times
a week (by phone) for outpatients.
- The child or parent will complete a daily diary of bowel movements.
- A registered dietitian will evaluate the child's nutritional status periodically (by
phone).
Children who are not constipated when they enter the study will receive a stool softener
every day to prevent constipation. Children who become constipated during the study will be
treated as needed. Patients will be followed for 7 days after the last dose of vinca
alkaloid or narcotic for a maximum of 6 weeks.
Children with cancer are treated with complex therapies including chemotherapy, radiation,
surgical interventions and biotherapy. Treatment with vinca alkaloids and/or narcotics
combined with significant lifestyle changes secondary to the disease process can have a
negative impact on the child's bowel elimination status. In trying to preserve the child's
health and well being, constipation can be minimized or even prevented as an unwanted side
effect of the treatments or disease condition.
Despite the widespread knowledge that constipation is prevalent in oncology patients,
evidence shows that cancer treatment plans often overlook constipation and reflect the lack
of consensus for effective assessment, treatment, and management. The research literature
provides a database for addressing particular aspects of constipation. However, few studies
address all the factors that affect bowel function and fewer still have recruited pediatric
populations.
The Constipation Assessment Scale (CAS) is a valid and reliable measure found to be
predictive of the presence and severity of constipation in the adult population, however it
has never been tested in the pediatric population. A pilot study utilizing the CAS tool in
children diagnosed with cancer will be conducted. The process for evaluating the presence
and severity of constipation and the reliability and validity of the CAS tool will be
tested. The study population will consist of inpatients and outpatients less than or equal
to 21 years old, receiving weekly vinca alkaloids and/or narcotics greater than or equal to
2 times per day for pain management. Patients will be followed for 7 days after the last
dose of vinca alkaloid and/or narcotic for a maximum of 6 weeks. Patients will be assessed
on admission for bowel function and constipation. The admission assessment will include a
nursing and nutrition assessment, review of the history and physical, and the administration
of the CAS. Subsequent assessments include nursing, nutrition, administration of the CAS,
and a patient daily bowel diary.
All patients regardless of participation in the study will be prescribed interventions based
on the bowel prophylaxis and management guidelines established by the NCI POB staff. These
guidelines were generated from validated studies, using Medline's criteria for scientific
soundness and clinical relevance, in the oncology literature as well as from the experience
of the NCI POB staff.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |